Dow GS - Search Results

1

A Planned Trial to Evaluate the Safety and Efficacy of Tafenoquine + Atovaquone/Azithromycin in Hospitalized Patients With Babesiosis.

Dow GS, Smith B. Dow GS, et al. J Infect Dis. 2024 Jul 25;230(1):271-272. doi: 10.1093/infdis/jiae193. J Infect Dis. 2024. PMID: 39052754 No abstract available.

2

[No title available]

[No authors listed] [No authors listed] PMID: 38712959

3

A phase II, double blind, placebo-controlled, randomized evaluation of the safety and efficacy of tafenoquine in patients with mild-moderate COVID-19 disease.

Dow GS, Smith BL. Dow GS, et al. New Microbes New Infect. 2022 Jun 1;47:100986. doi: 10.1016/j.nmni.2022.100986. eCollection 2022 Apr-May. New Microbes New Infect. 2022. PMID: 35668841 Free PMC article.

4

Blood Schizonticidal Activity and Safety of Tafenoquine When Administered as Chemoprophylaxis to Healthy, Nonimmune Participants Followed by Blood Stage Plasmodium falciparum Challenge: A Randomized, Double-blind, Placebo-controlled Phase 1b Study.

McCarthy JS, Smith B, Reid M, Berman J, Marquart L, Dobbin C, West L, Read LT, Dow GS. McCarthy JS, et al. Among authors: dow gs. Clin Infect Dis. 2019 Jul 18;69(3):480-486. doi: 10.1093/cid/ciy939. Clin Infect Dis. 2019. PMID: 30388194 Clinical Trial.

5

Tafenoquine is not neurotoxic following supertherapeutic dosing in rats.

Dow GS, Brown T, Reid M, Smith B, Toovey S. Dow GS, et al. Travel Med Infect Dis. 2017 May-Jun;17:28-34. doi: 10.1016/j.tmaid.2017.05.006. Epub 2017 May 8. Travel Med Infect Dis. 2017. PMID: 28495355 Free article.

6

Altered drug susceptibility during host adaptation of a Plasmodium falciparum strain in a non-human primate model.

Obaldía N 3rd, Dow GS, Gerena L, Kyle D, Otero W, Mantel PY, Baro N, Daniels R, Mukherjee A, Childs LM, Buckee C, Duraisingh MT, Volkman SK, Wirth DF, Marti M. Obaldía N 3rd, et al. Among authors: dow gs. Sci Rep. 2016 Feb 16;6:21216. doi: 10.1038/srep21216. Sci Rep. 2016. PMID: 26880111 Free PMC article.

7

Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries.

Dow GS, Liu J, Lin G, Hetzell B, Thieling S, McCarthy WF, Tang D, Smith B. Dow GS, et al. Malar J. 2015 Nov 26;14:473. doi: 10.1186/s12936-015-0991-x. Malar J. 2015. PMID: 26610844 Free PMC article. Clinical Trial.

8

A retrospective analysis of the protective efficacy of tafenoquine and mefloquine as prophylactic anti-malarials in non-immune individuals during deployment to a malaria-endemic area.

Dow GS, McCarthy WF, Reid M, Smith B, Tang D, Shanks GD. Dow GS, et al. Malar J. 2014 Feb 6;13:49. doi: 10.1186/1475-2875-13-49. Malar J. 2014. PMID: 24502679 Free PMC article.

9

Ketotifen is an antimalarial prodrug of norketotifen with blood schizonticidal and liver-stage efficacy.

Milner E, Sousa J, Pybus B, Auschwitz J, Caridha D, Gardner S, Grauer K, Harris E, Hickman M, Kozar MP, Lee P, Leed S, Li Q, Melendez V, Moon J, Ngundam F, O'Neil M, Parriott S, Potter B, Sciotti R, Tangteung A, Dow GS. Milner E, et al. Among authors: dow gs. Eur J Drug Metab Pharmacokinet. 2012 Mar;37(1):17-22. doi: 10.1007/s13318-012-0080-2. Eur J Drug Metab Pharmacokinet. 2012. PMID: 22314893

10

Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta).

Dow GS, Gettayacamin M, Hansukjariya P, Imerbsin R, Komcharoen S, Sattabongkot J, Kyle D, Milhous W, Cozens S, Kenworthy D, Miller A, Veazey J, Ohrt C. Dow GS, et al. Malar J. 2011 Jul 29;10:212. doi: 10.1186/1475-2875-10-212. Malar J. 2011. PMID: 21801400 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

28 results

Search Page

Filters